Business Update21 Jul 2024, 07:09 pm
Rossari Biotech Reports 19.3% YoY Revenue Growth in Q1 FY25
AI Summary
Rossari Biotech Limited, a Specialty-Chemicals manufacturer, has announced its financial results for the quarter ended June 30, 2024. The company reported a 19.3% YoY increase in revenue from operations, reaching Rs. 489.7 crore compared to Rs. 410.6 crore in Q1 FY24. EBITDA improved by 12.5% to Rs. 64.9 crore, and PAT increased by 19.5% to Rs. 34.9 crore. Standalone, revenue from operations stood at Rs. 300.7 crore, up 16.4% from Q1 FY24.
Key Highlights
- Q1 FY25 revenues at Rs. 489.7 Cr, up 19.3% YoY
- EBITDA for Q1 FY25 at Rs. 64.9 Cr, up 12.5% YoY
- PAT for Q1 FY25 increased by 19.5% to Rs. 34.9 Cr
- Standalone revenue from operations stood at Rs. 300.7 crore, up 16.4%
- EBITDA margin at 13.3% and EPS (Diluted) at Rs. 6.3